ISSN: 2278-0238

Revista Internacional de Pesquisa e Desenvolvimento em Farmácia e Ciências da Vida

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

CoMFA -3D QSAR APPROCH IN DRUG DESIGN

Sandip Sen, N.A.Farooqui , T.S.Easwari, Bishwabara Roy

Progress in medicinal chemistry and in drug design depends on our ability to understand the interactions of drugs with their biological targets. Classical QSAR studies describe biological activity in terms of physicochemical properties of substituents in certain positions of the drug molecules. The detailed discussion of the present state of the art should enable scientists to further develop and improve these powerful new tools. Comparative Molecular Field Analysis (CoMFA) is a mainstream and down-toearth 3D QSAR technique in the coverage of drug discovery and development. Even though CoMFA is remarkable for high predictive capacity, the intrinsic data-dependent characteristic still makes this methodology certainly be handicapped by noise. It's well known that the default settings in CoMFA can bring about predictive QSAR models, in the meanwhile optimized parameters was proven to provide more predictive results. Accordingly, so far numerous endeavors have been accomplished to ameliorate the CoMFA model’s robustness and predictive accuracy by considering various factors, including molecular conformation and alignment, field descriptors and grid spacing. In the present article we are going to discuss the basic approaches of CoMFA in drug design.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado.